Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $64 to $59.
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $64 to $59.
